156 related articles for article (PubMed ID: 30719865)
1. Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3-month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabetic Patients: Long-term Use study.
Tobe K; Maegawa H; Tabuchi H; Nakamura I; Uno S
J Diabetes Investig; 2019 Sep; 10(5):1262-1271. PubMed ID: 30719865
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world clinical practice: Results of 3-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
Utsunomiya K; Senda M; Kakiuchi S; Kameda H; Tamura M; Kurihara Y; Gunji R; Fujii S; Fujiwara H; Kaku K
J Diabetes Investig; 2019 Sep; 10(5):1272-1283. PubMed ID: 30702214
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.
Kashiwagi A; Yoshida S; Nakamura I; Kazuta K; Ueyama E; Takahashi H; Satomi H; Kosakai Y; Kawamuki K
J Diabetes Investig; 2016 Jul; 7(4):544-54. PubMed ID: 27181576
[TBL] [Abstract][Full Text] [Related]
4. Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open-label study (SOAR-KOBE Study).
Miura H; Sakaguchi K; Okada Y; Yamada T; Otowa-Suematsu N; So A; Komada H; Hirota Y; Ohara T; Kuroki Y; Hara K; Matsuda T; Kishi M; Takeda A; Yokota K; Tamori Y; Ogawa W
J Diabetes Investig; 2019 Sep; 10(5):1254-1261. PubMed ID: 30688412
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of ipragliflozin in elderly versus non-elderly Japanese patients with type 2 diabetes mellitus: a subgroup analysis of the STELLA-LONG TERM study.
Maegawa H; Tobe K; Tabuchi H; Nakamura I; Uno S
Expert Opin Pharmacother; 2018 Mar; 19(4):327-336. PubMed ID: 29388470
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study.
Nakamura I; Maegawa H; Tobe K; Tabuchi H; Uno S
Expert Opin Pharmacother; 2018 Feb; 19(3):189-201. PubMed ID: 29185822
[TBL] [Abstract][Full Text] [Related]
7. Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study.
Nakamura I; Maegawa H; Tobe K; Uno S
Adv Ther; 2019 Apr; 36(4):923-949. PubMed ID: 30767112
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics.
Osonoi T; Nakamoto S; Saito M; Tamasawa A; Ishida H; Osonoi Y
J Diabetes Investig; 2018 Mar; 9(2):341-353. PubMed ID: 28644562
[TBL] [Abstract][Full Text] [Related]
9. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.
Inoue H; Morino K; Ugi S; Tanaka-Mizuno S; Fuse K; Miyazawa I; Kondo K; Sato D; Ohashi N; Ida S; Sekine O; Yoshimura M; Murata K; Miura K; Arima H; Maegawa H;
J Diabetes Investig; 2019 Jul; 10(4):1012-1021. PubMed ID: 30536746
[TBL] [Abstract][Full Text] [Related]
10. Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes.
Takahashi K; Cho KY; Nakamura A; Miya A; Miyoshi A; Yamamoto C; Nomoto H; Niwa H; Takahashi K; Manda N; Kurihara Y; Aoki S; Ito YM; Atsumi T; Miyoshi H
J Diabetes Investig; 2019 Mar; 10(2):429-438. PubMed ID: 30136403
[TBL] [Abstract][Full Text] [Related]
11. Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM).
Tobe K; Maegawa H; Nakamura I; Uno S
Endocr J; 2021 Aug; 68(8):905-918. PubMed ID: 33827996
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of ipragliflozin in elderly versus non-elderly Japanese type 2 diabetes mellitus patients: 12 month interim results of the STELLA-LONG TERM study.
Maegawa H; Tobe K; Nakamura I; Uno S
Curr Med Res Opin; 2019 Nov; 35(11):1901-1910. PubMed ID: 31347926
[No Abstract] [Full Text] [Related]
13. Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice.
Maegawa H; Tobe K; Tabuchi H; Nakamura I
Expert Opin Pharmacother; 2016 Oct; 17(15):1985-94. PubMed ID: 27463414
[TBL] [Abstract][Full Text] [Related]
14. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world practice: Results of 12-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
Utsunomiya K; Senda M; Kakiuchi S; Kameda H; Tamura M; Kurihara Y; Gunji R; Fujii S; Kaku K
J Diabetes Investig; 2020 Jan; 11(1):132-141. PubMed ID: 31197929
[TBL] [Abstract][Full Text] [Related]
15. Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: a subgroup analysis of the STELLA-LONG TERM study (3-month interim results).
Tabuchi H; Maegawa H; Tobe K; Nakamura I; Uno S
Endocr J; 2019 Jan; 66(1):31-41. PubMed ID: 30393249
[TBL] [Abstract][Full Text] [Related]
16. Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Interim results of a post-marketing surveillance study.
Terauchi Y; Yokote K; Nakamura I; Sugamori H
Expert Opin Pharmacother; 2016; 17(4):463-71. PubMed ID: 26800061
[TBL] [Abstract][Full Text] [Related]
17. Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM).
Nakamura I; Maegawa H; Tobe K; Uno S
Expert Opin Pharmacother; 2021 Feb; 22(3):373-387. PubMed ID: 33012212
[TBL] [Abstract][Full Text] [Related]
18. Long-term (52-week) efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open-label extension of a phase III study.
Kaku K; Isaka H; Sakatani T; Toyoshima J
J Diabetes Investig; 2020 May; 11(3):662-671. PubMed ID: 31743569
[TBL] [Abstract][Full Text] [Related]
19. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT).
Utsunomiya K; Kakiuchi S; Senda M; Fujii S; Kurihara Y; Gunji R; Koshida R; Kameda H; Tamura M; Kaku K
J Diabetes Investig; 2020 Jul; 11(4):906-916. PubMed ID: 32034997
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]